Results:

(English) ESG News Review 5 – 11 April 2014

14 04 2014

Désolé, cet article est seulement disponible en Anglais Américain.


(English) ESG News Review 17 — 23 August 2013

26 08 2013

Désolé, cet article est seulement disponible en Anglais Américain.


Pharma Reputations: Managing Perceptions

14 08 2012

Geneva-based Covalence, a company that markets the information system, EthicalQuote, has observed that pharma is not keeping pace with other industries in terms of the overall balance of global good and bad news coverage in four broad ethical areas: labour standards, waste management, product social utility and human rights policy. “The pharma industry is losing […]


Drug Firms Say They’ll Take Closer Look at the Docs They Pay

18 11 2010

Several of the nation’s largest pharmaceutical companies said they plan to tighten screening of physicians who promote their drugs after ProPublica reported last month that more than 250 of them had been sanctioned for misconduct. Eli Lilly and Co. said that next year, for the first time, it would hire an outside firm to search […]


World Business and Development Award winners: Fighting poverty can benefit business

21 09 2010

Ten companies were recognized today at this year’s World Business and Development Awards (WBDA) for their efforts in improving the lives of some of the world’s most disadvantaged communities. The winning companies are engaged in diverse initiatives such as providing low-income housing in Mexico; assisting farmers in Sierra Leone integrate into sorghum value chains, and […]


Eli Lilly to disclose financial ties to doctors, a drug industry first

24 09 2008

The drug maker Eli Lilly & Co. plans to create a public database listing the names of physicians it pays for speaking engagements and consulting services, the company will announce Wednesday. The new policy puts Lilly at the forefront of the drug industry as the firm seeks to cement its reputation as a leader in […]


Pharmas Challenged by Product Risk and Philanthropy Fatigue – Covalence Pharmaceutical Industry Report 2008

9 09 2008

Increased attention on product human risk and smaller media coverage of drug donations have challenged Pharmaceuticals’ ethical reputation last year, states a report published today by Geneva-based research firm Covalence — Covalence Pharmaceutical Industry Report 2008. The pharmaceutical industry dropped from the first to the third rank of Covalence all-time EthicalQuote ranking across 10 industries. […]


Eli Lilly Adds Support for Drug Transparency Laws

27 05 2008

Amid increasing governmental and professional concerns about payments to physicians by pharmaceutical companies, major drug manufacturer Eli Lilly announced its support for legislation to increase public trust in the healthcare industry. Independent studies have shown a significant financial link between the drug industry and practicing physicians. Ninety-four percent of doctors reported that they have some […]


The Burden of Innovation – Covalence Pharmaceutical Industry Report 2007

29 08 2007

Pharmaceutical companies carry increasing ethical risks related to innovation, states a report released on 29 August 2007 by Geneva-based ethical reputation research firm Covalence, Covalence Pharmaceutical Industry Report 2007. These innovation-related risks deal with intellectual property rights, drug pricing, clinical trials, drug side-effects and transparency. In terms of ethical reputation, innovation seems to bring more […]


After Sanctions, Doctors Get Drug Company Pay

3 06 2007

A decade ago the Minnesota Board of Medical Practice accused Dr. Faruk Abuzzahab of a “reckless, if not willful, disregard” for the welfare of 46 patients, 5 of whom died in his care or shortly afterward. The board suspended his license for seven months and restricted it for two years after that. But Dr. Abuzzahab, […]